Drug Discovery World
JULY 20, 2023
Compounds can be printed neat at 10mM in dimethyl sulfoxide (DMSO), and a unique data point is generated per target-ligand interaction. The technique is suited for targeting proteins and structured RNA, developing heterobifunctional degrader molecules (e.g., PROTAC), and training AI drug discovery models.
Drug Discovery World
OCTOBER 4, 2022
New York-based Oligomerix is an emerging clinical-stage biotechnology company focused on developing disease-modifying therapeutics for neurodegenerative diseases characterised by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD) to Alzheimer’s disease (AD).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
FEBRUARY 22, 2024
With no in-house laboratory space, the company works closely with multiple international contract research organisations (CROs), including Axxam, which carry out all of the Libra R&D, from compound screening assays, to in vivo pharmacokinetic/pharmacodynamic and ADME work, as well as in vitro and in vivo pre-clinical safety assessments.
Drug Discovery World
JANUARY 23, 2023
They cannot be easily scaled or broadly applied to other therapeutic programs or disease areas, and the data generated from any compound screens will be narrowly focused on the target hypothesis. These steps are time-consuming and specific to answering a particular scientific question at hand. That’s where AI and ML come in.
Drug Discovery World
AUGUST 15, 2023
Manual patch-clamping of single cells has become a mainstay of functional electrophysiology, often used to follow up after novel hit compounds are identified by non-functional fluorescence or ligand binding methods, which are considerably higher in their throughput.
Expert insights. Personalized for you.
40 
Let's personalize your content